Cansu BÜYÜKTARAKÇI, Hesna BEKTAŞ, Hürrem BODUR, Aliye BAŞTUĞ

PARA-INFECTIOUS GUILLAIN BARRE SYNDROME IN A PATIENT DIAGNOSED WITH COVID-19

Accumulating evidence suggests the neurotropic characteristics of the SARS-CoV-2. Although the pathogenesis is unclear, the relationship between COVID-19 and Guillain Barre Syndrome (GBS) has been described previously. In this report, a 66-year-old male with para-infectious COVID-19-related GBS admitted with bilateral weakness in distal lower limbs was presented. Five days ago, since he had a risky contact with the COVID-19 patient, the SARS-CoV-2 PCR test was performed and resulted in positive. Favipiravir treatment was given as outpatient therapy. On the fifth day of antiviral treatment, he had applied to Emergency Department with two days of muscle weakness of lower extremities consistent with GBS; hence lumbar punction was performed. The cerebrospinal fluid examination revealed albumin-cytological dissociation. Despite the administration of immunoglobulin infusions, neurological findings worsened, dysphagia, and facial paralysis occurred. Although he was stable for COVID, he was followed up in the intensive care unit for plasmapheresis and then intubated for the respiratory involvement of GBS. Early diagnosis and treatment are critical in GBS related to COVID-19. Since para-infectious COVID-19-related GBS has poor outcomes, clinicians should be aware of this kind of complication to manage patients as it’s supposed to be.

PDF

___

1. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Hu Y. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study (preprint). 2020. (doi:10.1101/2020.02.22.20026500).
2. Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, Narayanaswami P. COVID-19–associated Guillain-Barré syndrome: The early pandemic experience. Muscle & nerve. 2020;62:485-91.
3. Willison HJ, Jacobs BC, Van Doorn PA. Guillain-barre syndrome. The Lancet. 2016;388:717-27.
4. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet Neurology. 2020;19:383-4.
5. Kajumba MM, Kolls BJ, Koltai DC, Kaddumukasa M, Kaddumukasa M, Laskowitz DT. COVID19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications. SN comprehensive clinical medicine. 2020:1-13.
6. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33-43.
7. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Archives of neurology. 2001;58:893-8.
8. Swan A, Van Doorn P, Hughes R. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;19.
9. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews. 2012.
10.Hughes RA, Swan AV, Raphaël J-C, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130:2245-57.